
Megan S Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2593381/publications.pdf Version: 2024-02-01



MECAN SLIM

#	Article	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
2	International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	1.4	381
3	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. Journal of Clinical Oncology, 2017, 35, 3215-3221.	1.6	315
4	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome. Nature Communications, 2015, 6, 8470.	12.8	177
5	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Advances, 2020, 4, 6039-6050.	5.2	94
6	Target and Agent Prioritization for the Children's Oncology Group—National Cancer Institute Pediatric MATCH Trial. Journal of the National Cancer Institute, 2017, 109, .	6.3	85
7	Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers, 2018, 10, 99.	3.7	59
8	Activating <i>KRAS</i> mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. Journal of Pathology, 2016, 239, 394-398.	4.5	55
9	T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. Clinical Cancer Research, 2017, 23, 2506-2515.	7.0	49
10	Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation. Frontiers in Genetics, 2020, 11, 577152.	2.3	46
11	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. Journal of Clinical Oncology, 2020, 38, 3062-3070.	1.6	42
12	Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood, 2021, 137, 3595-3603.	1.4	40
13	Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. Oncolmmunology, 2018, 7, e1442164.	4.6	34
14	Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. Proceedings of the United States of America, 2017, 114, 6581-6586.	7.1	32
15	Pathology and genetics of anaplastic large cell lymphoma. Seminars in Diagnostic Pathology, 2020, 37, 57-71.	1.5	31
16	New Insights into Lymphoma Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 193-217.	22.4	27
17	Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget, 2018, 9, 21820-21830.	1.8	24
18	Mature T―and <scp>NK</scp> â€cell nonâ€Hodgkin lymphoma in children and young adolescents. British Journal of Haematology, 2016, 173, 573-581.	2.5	23

Megan S Lim

#	Article	IF	CITATIONS
19	Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. Laboratory Investigation, 2017, 97, 962-970.	3.7	21
20	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American Journal of Hematology, 2020, 95, 1553-1561.	4.1	18
21	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Reports Medicine, 2020, 1, 100158.	6.5	18
22	lbrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, <i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncolmmunology, 2019, 8, e1512455.	4.6	17
23	Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. British Journal of Haematology, 2017, 177, 601-611.	2.5	15
24	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget, 2017, 8, 113895-113909.	1.8	15
25	Mass spectrometry and proteomics in hematology. Seminars in Hematology, 2019, 56, 52-57.	3.4	11
26	Transcriptome and unique cytokine microenvironment of Castleman disease. Modern Pathology, 2022, 35, 451-461.	5.5	10
27	The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. Oncogene, 2020, 39, 2103-2117.	5.9	9
28	Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56 ^{Dim} NK cells. Innate Immunity, 2019, 25, 294-304.	2.4	8
29	Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL. Blood, 2019, 134, 1510-1510.	1.4	8
30	Precision Medicine for Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 2829-2831.	7.0	7
31	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. American Journal of Clinical Pathology, 2019, 152, 277-301.	0.7	6
32	Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Hematological Oncology, 2022, 40, 191-201.	1.7	6
33	Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain. Blood, 2019, 134, 1540-1540.	1.4	3
34	A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families. Vaccines, 2020, 8, 631.	4.4	2
35	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma. Cancers, 2020, 12, 1669.	3.7	2
36	Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease. Blood, 2021, 138, 1623-1623.	1.4	2

MEGAN S LIM

#	Article	IF	CITATIONS
37	The disease course of Castleman disease patients with fatal outcomes in the <scp>ACCELERATE</scp> registry. British Journal of Haematology, 2022, , .	2.5	2
38	NPM-ALK Mediated Tyrosine Phosphorylation of ATP Citrate Lyase Regulates Lipid Metabolism and Promotes Oncogenesis of Anaplastic Large Cell Lymphoma. Blood, 2015, 126, 465-465.	1.4	1
39	Epiproteomic Landscape and Histone Code of Cutaneous T-Cell Lymphoma/Sézary Syndrome. Blood, 2018, 132, 780-780.	1.4	1
40	A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma. Blood, 2021, 138, 711-711.	1.4	1
41	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	2.5	1
42	N-Glycoproteomic Landscape of Human Lymphoid Cancers Reveals Novel Biomarkers and Potential Therapeutic Targets. Blood, 2015, 126, 697-697.	1.4	0
43	Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease. Blood, 2021, 138, 1622-1622.	1.4	0
44	Significance of <i>RUNX1</i> mutation in <i>BCR-ABL1</i> positive acute myeloid leukemia – a diagnostic dilemma in a young woman with persistent bleeding. Leukemia and Lymphoma, 2022, , 1-5.	1.3	0